Clinical Trials
16 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04649359 2026-05-19
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
Phase 2 Active not recruiting
NCT04634552 2026-05-08
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05083169 2026-05-08
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03319667 2026-05-04
IMROZ
Sanofi
Phase 3 Active not recruiting
NCT04246047 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03761108 2026-04-20
LINKER-MM1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT03301220 2026-04-13
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03652064 2026-04-08
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT03201965 2025-11-26
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 3 Completed
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03525678 2025-09-03
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
GlaxoSmithKline
Phase 2 Completed
NCT03548207 2025-07-30
CARTITUDE-1
Janssen Research & Development, LLC
Phase 1/2 Completed